This is a Phase II open-label study to assess the efficacy and safety of camizestrant (a next-generation oral selective oestrogen receptor degrader - SERD) compared to standard endocrine therapy (aromatase inhibitor or tamoxifen) for patients with early ER-positive HER2-negative breast cancer and an intermediate-to-high or high risk of recurrence and who have completed definitive locoregional treatment and have no evidence of disease.
New Zealand sites for this trial will be Auckland, Waikato and Palmerston North.
Read more about this trial here.
29 April 2024
